The collaboration aims to accelerate cell and gene therapies.
Integrated cell and gene therapy CDMO eXmoor Pharma has partnered with university KU Leuven to support new a cell and gene therapy hub.
“This partnership with a leading CDMO represents the final critical step in our mission to streamline the path from discovery to clinical impact, ensuring that our advanced AAV vector technologies can reach patients more efficiently and effectively,” said principal investigator and head of KU Leuven’s Trellis Research Group Els Henckaerts.
The cell and gene therapy hub, created by KU Leuven and university hospitals UZ Leuven, is designed as a transitional vehicle for gene therapy assets.
The collaboration aims to accelerate cell and gene therapies from bench to trials, combining scientific, regulatory and manufacturing capabilities.
One of the main focusses of the partnership will be the development of adeno-associated virus (AAV) gene therapy programmes.
Overall, the collaboration spans four key areas: joint AAV cell line development, strategic consultancy, AAV platform process development and PD and GMP manufacturing support.
“Over the years, our lab has worked tirelessly to bridge the gap between academic innovation and real-world therapeutic applications,” said Henckaerts.
“Gene therapy holds immense promise for transforming the lives of patients.”
